Scinai Immunotherapeutics Q3 2024 Earnings Report

Scinai Immunotherapeutics EPS Results

• Actual EPS: $8.40
• Consensus EPS: N/A
• Beat/Miss: N/A
• One Year Ago EPS: N/A

Scinai Immunotherapeutics Revenue Results

• Actual Revenue: N/A
• Expected Revenue: N/A
• Beat/Miss: N/A
• YoY Revenue Growth: N/A

Scinai Immunotherapeutics Announcement Details

• Quarter: Q3 2024
• Date: 11/22/2024
• Time: Before Market Opens
• Conference Call Date: Friday, November 22, 2024
• Conference Call Time: 7:00AM ET

Scinai Immunotherapeutics (NASDAQ:SCNI) Inc is a clinical-stage biotechnology company dedicated to developing novel small-molecule therapies that enhance the immune system’s capacity to recognize and destroy cancer cells. The company’s research emphasizes checkpoint modulation and the discovery of compounds designed to work in concert with established immuno-oncology treatments across a range of solid tumors.

Scinai’s pipeline comprises preclinical and early-stage candidates, and the company relies on collaborations with academic institutions and contract research organizations to advance its discovery and development efforts. These partnerships support lead optimization, biomarker identification and the generation of preclinical efficacy and safety data in preparation for eventual clinical evaluation.

Headquartered in the United States, Scinai Immunotherapeutics conducts its research and development activities primarily in North America while pursuing strategic alliances to extend its presence into European and Asian markets. The company remains focused on translating its scientific platform into robust therapeutic options, underpinned by rigorous preclinical validation and translational research initiatives.